Annals of Surgical Oncology

, Volume 15, Issue 4, pp 1193–1201

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

Authors

    • Department of Radiation Oncology, The Second Affiliated Hospital; and Cancer InstituteZhejiang University School of Medicine
    • Cancer InstituteZhejiang University
    • Department of Oncology, Radiology and Clinical Immunology, Rudbeck LaboratoryUppsala University Hospital
  • Liming Sheng
    • Cancer InstituteZhejiang University
  • Yongjie Shui
    • Cancer InstituteZhejiang University
  • Qiongge Hu
    • Department of Radiation Oncology, The Second Affiliated Hospital; and Cancer InstituteZhejiang University School of Medicine
  • Hans Nordgren
    • Department of Genetics and Pathology, Rudbeck LaboratoryUppsala University Hospital
  • Jorgen Carlsson
    • Department of Oncology, Radiology and Clinical Immunology, Rudbeck LaboratoryUppsala University Hospital
Head and Neck Oncology

DOI: 10.1245/s10434-007-9771-3

Cite this article as:
Wei, Q., Sheng, L., Shui, Y. et al. Ann Surg Oncol (2008) 15: 1193. doi:10.1245/s10434-007-9771-3

Abstract

Background

There are several substances available to target members of the epidermal growth factor receptor (EGFR) family, both for imaging in nuclear medicine and for various forms of therapy. The level and stability of expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as a target in systemic tumor therapy. To date, the expression of EGFR family members has only been determined in primary laryngeal carcinomas, and we have not found published data regarding the receptor status in corresponding metastatic lesions.

Methods

Expression of EGFR, HER2, and HER3 was investigated immunohistochemically in both lymph node metastases and corresponding primary laryngeal squamous carcinomas (n = 40).

Results

EGFR overexpression (2+ or 3+) was found in 87.5% (35/40) of the laryngeal primary tumors and 82.5% (33/40) of the corresponding lymph node metastases. There was a good agreement between the primary tumors and the paired metastases regarding EGFR expression. HER2 overexpression was found in only four cases (10.5%) of the studied primary tumors and in all cases the HER2 expression was retained in the paired metastases. Another two metastases gained HER2 status when compared to the corresponding primary tumors. Strong HER3 staining was found in 26.7% of both the primary tumors and the corresponding metastases.

Conclusions

The high frequency and stability in EGFR expression is encouraging for efforts to use EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabeled antibodies) for therapy of laryngeal carcinoma. For a few laryngeal carcinoma patients with HER2 overexpression, anti-HER2 agents could possibly be used.

Keywords

Laryngeal carcinomaEGFRHER2HER3MetastasisReceptor overexpression

Copyright information

© Society of Surgical Oncology 2007